[go: up one dir, main page]

PL2130044T3 - Sposób identyfikowania ryzyka rozwoju chorób tarczycy - Google Patents

Sposób identyfikowania ryzyka rozwoju chorób tarczycy

Info

Publication number
PL2130044T3
PL2130044T3 PL08725657T PL08725657T PL2130044T3 PL 2130044 T3 PL2130044 T3 PL 2130044T3 PL 08725657 T PL08725657 T PL 08725657T PL 08725657 T PL08725657 T PL 08725657T PL 2130044 T3 PL2130044 T3 PL 2130044T3
Authority
PL
Poland
Prior art keywords
thyroid disorder
identifying risk
identifying
risk
thyroid
Prior art date
Application number
PL08725657T
Other languages
English (en)
Inventor
David H. Margolin
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of PL2130044T3 publication Critical patent/PL2130044T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/635Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70592CD52
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/046Thyroid disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL08725657T 2007-02-16 2008-02-15 Sposób identyfikowania ryzyka rozwoju chorób tarczycy PL2130044T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90173207P 2007-02-16 2007-02-16

Publications (1)

Publication Number Publication Date
PL2130044T3 true PL2130044T3 (pl) 2017-04-28

Family

ID=39434244

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08725657T PL2130044T3 (pl) 2007-02-16 2008-02-15 Sposób identyfikowania ryzyka rozwoju chorób tarczycy

Country Status (21)

Country Link
US (3) US20100136587A1 (pl)
EP (2) EP2538217A1 (pl)
JP (2) JP5662684B2 (pl)
CN (2) CN101657721B (pl)
AU (1) AU2008219097B2 (pl)
BR (1) BRPI0807601B8 (pl)
CA (1) CA2678199A1 (pl)
CY (1) CY1118663T1 (pl)
DK (1) DK2130044T3 (pl)
ES (1) ES2612558T3 (pl)
HR (1) HRP20170121T1 (pl)
HU (1) HUE031421T2 (pl)
IL (2) IL200314A (pl)
LT (1) LT2130044T (pl)
MX (1) MX2009008642A (pl)
PL (1) PL2130044T3 (pl)
PT (1) PT2130044T (pl)
RS (1) RS55636B1 (pl)
RU (1) RU2013120485A (pl)
SI (1) SI2130044T1 (pl)
WO (1) WO2008103292A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9498528B2 (en) 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
FR2934129B1 (fr) * 2008-07-24 2014-05-02 Oreal Procede de traitement cosmetique.
JP5833924B2 (ja) * 2008-09-19 2015-12-16 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 多発性硬化症および治療応答の同定および予測のための方法
CN106257288A (zh) * 2016-08-15 2016-12-28 余洋 一种血清TPOAb IgG4水平检测方法
US11327074B2 (en) 2018-07-02 2022-05-10 Siemens Healthcare Diagnostics Inc. Thyroid peroxidase autoantibody immunoassay
KR102469743B1 (ko) * 2020-06-10 2022-11-22 주식회사 타이로스코프 약물 복용에 따른 갑상선 기능 모니터링 방법, 이를 수행하는 모니터링 서버 및 사용자 단말
EP4001919A1 (en) * 2020-11-13 2022-05-25 Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal Predictive biomarkers of autoimmunity in patients treated with alemtuzumab
WO2024158259A1 (ko) * 2023-01-27 2024-08-02 주식회사 타이로스코프 대상에 대한 갑상선기능이상증의 예측방법 및 시스템

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
GB2265713A (en) * 1992-05-16 1993-10-06 R S R Limited Assay for autoantibodies against thyroglobulin or thyroid peroxidase
DE19710211C2 (de) * 1997-03-12 1999-12-16 Brahms Diagnostica Gmbh Verfahren zur Bestimmung von Schilddrüsen-Autoantikörpern
GB9823397D0 (en) * 1998-10-27 1998-12-23 Rsr Ltd Assays for thyroid autoantibodies
JP2008523785A (ja) * 2004-10-12 2008-07-10 カーランテック,インコーポレーテッド 神経変性、自己免疫脱髄、および糖尿病のウイルス病原に対する動物モデル系
US9498528B2 (en) 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)

Also Published As

Publication number Publication date
PT2130044T (pt) 2017-02-03
AU2008219097B2 (en) 2011-06-23
EP2538217A1 (en) 2012-12-26
MX2009008642A (es) 2009-10-20
US10648986B2 (en) 2020-05-12
US20130095507A1 (en) 2013-04-18
JP6058585B2 (ja) 2017-01-11
RS55636B1 (sr) 2017-06-30
IL242391A (en) 2017-09-28
JP5662684B2 (ja) 2015-02-04
BRPI0807601B8 (pt) 2021-07-27
CN108303546B (zh) 2023-01-03
IL200314A (en) 2015-11-30
RU2009134313A (ru) 2011-03-27
EP2130044B1 (en) 2016-10-26
HRP20170121T1 (hr) 2017-03-24
JP2010519512A (ja) 2010-06-03
DK2130044T3 (en) 2017-02-06
LT2130044T (lt) 2017-02-10
ES2612558T3 (es) 2017-05-17
AU2008219097A1 (en) 2008-08-28
BRPI0807601B1 (pt) 2021-02-23
CY1118663T1 (el) 2017-07-12
WO2008103292A1 (en) 2008-08-28
CN101657721B (zh) 2018-02-23
BRPI0807601A2 (pt) 2014-05-06
SI2130044T1 (sl) 2017-03-31
EP2130044A1 (en) 2009-12-09
JP2014149313A (ja) 2014-08-21
CN108303546A (zh) 2018-07-20
CN101657721A (zh) 2010-02-24
HK1257419A1 (zh) 2019-10-18
CA2678199A1 (en) 2008-08-28
US20100136587A1 (en) 2010-06-03
US20170307629A1 (en) 2017-10-26
US9664688B2 (en) 2017-05-30
HUE031421T2 (hu) 2017-07-28
IL200314A0 (en) 2010-04-29
RU2013120485A (ru) 2014-11-20

Similar Documents

Publication Publication Date Title
IL242391A (en) A method for identifying risk of thyroid disorder
IL239277A0 (en) A method for identifying risk factors for diseases
GB201111162D0 (en) A riser and a method for identifying a riser
IL210660A0 (en) Method and system for filming
PT2096102E (pt) Processo para a produção de metileno-difenil-diisocianatos
PL2325648T3 (pl) Sposób wykrywania nowotworów
EP2272009A4 (en) SYSTEM AND METHOD FOR MONITORING USE
EP2373558A4 (en) METHOD AND SYSTEM FOR PROVIDING DOCK ASSISTANCE
GB0813278D0 (en) Method for inhibiting corrosion
GB2446670C (en) Inspection method
GB2465502B (en) Method for identifying and selecting cardiomyocytes
EP2270480A4 (en) ANALYTICAL METHOD
GB2457927B (en) Method and system for resolving deadlocks
EG26381A (en) Method for the identification of oxidizing bacteria for propane
GB0817384D0 (en) Method of providing location data
ZA200803212B (en) Method for determining preeclampsia risk
GB201008346D0 (en) Methods and compounds for phototransfer
EP2438194A4 (en) METHODS OF SCREENING AND IDENTIFYING COMPOUNDS
EP2274534A4 (en) METHOD FOR IDENTIFYING POSITIONS OF BRAKE MONITORING DEVICES
GB0704761D0 (en) Method of identifying video assets
TWI365995B (en) Method for tetsing sata interface
ZA201101179B (en) Method and system for filming
ZA201005707B (en) Method for mining
IL190526A0 (en) Method for identifying patients
GB0710768D0 (en) Method of identifying biomarkers